Puget Sound Business Journal: Seattle Biotech AltPep Closes $23M Funding Round For Alzheimer’s Research
Seattle biotech AltPep Corp. closed a $23 million series A funding round last week, which will go toward its Alzheimer’s research.
The biotech is a portfolio company of IntuitiveX, a Seattle life science incubator. Altpep’s board of directors also made several additions, including Adaptive Biotechnologies CEO Chad Robins; David Goel, managing general partner and founded of Matrix Capital Management; and Joel Marcus, executive chairman and founder of Alexandria Real Estate Equities and Alexandria Venture Investments.